Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125808312 | 12580831 | 2 | F | 20160812 | 20160721 | 20160908 | EXP | US-MYLANLABS-2016M1029909 | MYLAN | SAN GABRIEL MC, EDDULA-CHANGALA B, TAN Y, LONGSHORE CT. ELECTROCONVULSIVE IN A SCHIZOPHRENIC PATIENT WITH NEUROLEPTIC MALIGNANT SYNDROME AND RHABDOMYOLYSIS. J-ECT 2015;31(3):197-200. | 0.00 | Y | 0.00000 | 20160908 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125808312 | 12580831 | 1 | PS | CLONAZEPAM. | CLONAZEPAM | 1 | Unknown | 1 MG, TID | Y | U | 75150 | 1 | MG | TID | |||||
| 125808312 | 12580831 | 2 | SS | CLONAZEPAM. | CLONAZEPAM | 1 | Unknown | 0.5 MG, BID | Y | U | 75150 | .5 | MG | BID | |||||
| 125808312 | 12580831 | 3 | SS | OLANZAPINE. | OLANZAPINE | 1 | Unknown | 20 MG DAILY | Y | U | 0 | ||||||||
| 125808312 | 12580831 | 4 | SS | OLANZAPINE. | OLANZAPINE | 1 | Unknown | 20 MG AT BEDTIME FOR 4 DAYS | Y | U | 0 | ||||||||
| 125808312 | 12580831 | 5 | SS | QUETIAPINE. | QUETIAPINE | 1 | Unknown | 50 MG DAILY; SLOWLY UP-TITRATED TO 100MG DAILY FOR 3 DAYS | Y | U | 0 | ||||||||
| 125808312 | 12580831 | 6 | SS | CLOZAPINE. | CLOZAPINE | 1 | Unknown | 12.5MG DAILY; SLOWLY TITRATED TO 175MG DAILY OVER 20 DAYS | Y | U | 0 | ||||||||
| 125808312 | 12580831 | 7 | C | HALOPERIDOL. | HALOPERIDOL | 1 | Oral | 5MG | 0 | ||||||||||
| 125808312 | 12580831 | 8 | C | HALOPERIDOL. | HALOPERIDOL | 1 | Intramuscular | 15MG | 0 | ||||||||||
| 125808312 | 12580831 | 9 | C | LORAZEPAM. | LORAZEPAM | 1 | Oral | 2MG | 0 | ||||||||||
| 125808312 | 12580831 | 10 | C | LORAZEPAM. | LORAZEPAM | 1 | Intramuscular | 5MG | 0 | ||||||||||
| 125808312 | 12580831 | 11 | C | LORAZEPAM. | LORAZEPAM | 1 | Unknown | 0 | |||||||||||
| 125808312 | 12580831 | 12 | C | CHLORPROMAZINE. | CHLORPROMAZINE | 1 | Intramuscular | 100MG | 0 | ||||||||||
| 125808312 | 12580831 | 13 | C | VALPROIC ACID. | VALPROIC ACID | 1 | Unknown | 500MG AT BEDTIME | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125808312 | 12580831 | 1 | Schizoaffective disorder depressive type |
| 125808312 | 12580831 | 3 | Schizoaffective disorder depressive type |
| 125808312 | 12580831 | 5 | Schizoaffective disorder depressive type |
| 125808312 | 12580831 | 6 | Schizoaffective disorder depressive type |
| 125808312 | 12580831 | 9 | Aggression |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125808312 | 12580831 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125808312 | 12580831 | Neuroleptic malignant syndrome | |
| 125808312 | 12580831 | Rhabdomyolysis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |